ARIA : Summary for ARIAD Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed
Loading...
Loading...
  • Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC
    Investor's Business Dailyyesterday

    Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC

    Ariad had to put off requests from a potential suitor in order to lock in an increased buyout offer from Takeda Pharmaceuticals.

  • American City Business Journalsyesterday

    Ariad played hardball to boost Takeda buyout price, federal filings show

    Takeda’s $5.2 billion acquisition of Ariad Pharmaceuticals on Jan. 9 valued the Cambridge cancer drug firm at $24 per share, a 75 percent premium over its previous closing stock price. A federal filing by Ariad (ARIA) on Thursday includes a lengthy play-by-play of the negotiations, beginning with a phone call on Dec. 2 between Ariad CEO Paris Panayiotopoulos and Takeda CEO Christophe Weber. During the call, Panayiotopoulos told Weber that if Takeda was interested in making a “broader” deal, it should do so in writing, according to the filing.

  • Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017
    Investor's Business Daily2 days ago

    Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017

    Biotechs have a lot riding on drug data in 2017 with nearly two dozen firms reporting data in four key segments.